Erratum: Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers (Cancer DOI:10.1002/cncr.28507);Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers

Cancer

Volumn 120, Issue 7, 2014, Pages 1068-1075

  Hettmer, Simone ^a,b,c,d   Archer, Natasha M ^a   Somers, Gino R ^e,f   Novokmet, Ana ^e   Wagers, Amy J ^c,d   Diller, Lisa ^a,b   Rodriguez Galindo, Carlos ^a,b   Teot, Lisa A ^a   Malkin, David ^e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Harvard University   (United States)

^d JOSLIN DIABETES CENTER   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

anaplasia; germline mutations; Li Fraumeni syndrome; rhabdomyosarcoma; TP53

Indexed keywords

PROTEIN P53;

ARTICLE; CANADA; CANCER SUSCEPTIBILITY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CARRIER; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MALE; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA;

ANAPLASIA; GERMLINE MUTATIONS; LI-FRAUMENI SYNDROME; RHABDOMYOSARCOMA; TP53;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; RHABDOMYOSARCOMA; YOUNG ADULT;

EID: 84899456367     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28666     Document Type: Erratum

References (44)

1. Parham DM,. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol. 2001; 14: 506-514.
2. Xia SJ, Pressey JG, Barr FG,. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther. 2002; 1: 97-104.
3. Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ,. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol. 2010; 222: 129-137.
4. Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A,. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med. 1998; 4: 619-622.
5. Tsumura H, Yoshida T, Saito H, Imanaka-Yoshida K, Suzuki N,. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene. 2006; 25: 7673-7679.
6. Rubin BP, Nishijo K, Chen HI, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 2011; 19: 177-191.
7. Corcoran RB, Scott MP,. A mouse model for medulloblastoma and basal cell nevus syndrome. J Neurooncol. 2001; 53: 307-318.
8. Ayan I, Luca J, Jaffe N, Strong L, Hansen M,. De novo germline mutations of the p53 gene in young children with sarcomas. Oncol Rep. 1997; 4: 679-683.
9. Beddis IR, Mott MG, Bullimore J,. Case report: nasopharyngeal rhabdomyosarcoma and Gorlin's naevoid basal cell carcinoma syndrome. Med Pediatr Oncol. 1983; 11: 178-179.
10. Cajaiba MM, Bale AE, Alvarez-Franco M, McNamara J, Reyes-Múgica M,. Rhabdomyosarcoma, Wilms tumor, and deletion of the patched gene in Gorlin syndrome. Nat Clin Pract Oncol. 2006; 3: 575-580.
11. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D,. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest. 1995; 95: 1606-1611.
12. Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA,. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A. 2006; 140: 8-16.
13. Heney D, Lockwood L, Allibone EB, Bailey CC,. Nasopharyngeal rhabdomyosarcoma and multiple lentigines syndrome: a case report. Med Pediatr Oncol. 1992; 20: 227-228.
14. Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS,. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet. 2011; 157: 83-89.
15. Steenman M, Westerveld A, Mannens M,. Genetics of Beckwith-Wiedemann syndrome-associated tumors: common genetic pathways. Genes Chromosomes Cancer. 2000; 28: 1-13.
16. Doros L, Yang J, Dehner L, et al. DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome. Pediatr Blood Cancer. 2012; 59: 558-560.
17. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet. 1994; 7: 91-97.
18. Frank AJ, Hernan R, Hollander A, et al. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res Mol Brain Res. 2004; 121: 137-140.
19. Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001; 38: 43-47.
20. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009; 27: 1250-1256.
21. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009; 27: e108-e109.
22. Kodet R, Newton WA Jr, Hamoudi AB, Asmar L, Jacobs DL, Maurer HM,. Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features. A report of the Intergroup Rhabdomyosarcoma Study. Am J Surg Pathol. 1993; 17: 443-453.
23. Qualman S, Lynch J, Bridge J, et al. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer. 2008; 113: 3242-3247.
24. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28: 622-629.
25. Soussi T, Asselain B, Hamroun D, et al. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res. 2006; 12: 62-69.
26. Cornelis RS, van Vliet M, van de Vijver MJ, et al. Three germline mutations in the TP53 gene. Hum Mutat. 1997; 9: 157-163.
27. Gonzalez KD, Buzin CH, Noltner KA, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 2009; 46: 689-693.
28. Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010; 47: 421-428.
29. Varley JM, Attwooll C, White G, et al. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene. 2001; 20: 2647-2654.
30. Wozniak A, Fryer A, Grimer R, Mc Dowell H,. Multiple malignancies in a child with de novo TP53 mutation. Pediatr Hematol Oncol. 2011; 28: 338-343.
31. Bougeard G, Sesboüé R, Baert-Desurmont S, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet. 2008; 45: 535-538.
32. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988; 48: 5358-5362.
33. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994; 54: 1298-1304.
34. Eeles RA,. Germline mutations in the TP53 gene. Cancer Surv. 1995; 25: 101-124.
35. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A,. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 2009; 27: 3391-3397.
36. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2002; 20: 2672-2679.
37. Felix CA, Kappel CC, Mitsudomi T, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992; 52: 2243-2247.
38. Takahashi Y, Oda Y, Kawaguchi K, et al. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol. 2004; 17: 660-669.
39. Kirsch DG, Dinulescu DM, Miller JB, et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med. 2007; 13: 992-997.
40. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001; 20: 4621-4628.
41. Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 20 2012; 148: 59-71.
42. Heerema-McKenney A, Wijnaendts LC, Pulliam JF, et al. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. Am J Surg Pathol. 2008; 32: 1513-1522.
43. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012; 488: 49-56.
44. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011; 12: 559-567.